ICER | Working Towards Fair Pricing, Fair Access, & Future ...
文章推薦指數: 80 %
ICER provides independent evaluations on the value of medical tests, treatments and delivery systems. FairPricing,FairAccess,FutureInnovation LearnmoreabouthowICERisworkingtoimprovetheUShealthcaresystem × OngoingAssessments&RecentResearch.Easyaccesstoourwork Alzheimer’sDisease Mar2023 AmyotrophicLateralSclerosis(ALS) Aug2022 EvaluatingandAdvancingHealthTechnologyAssessmentMethodsthatSupportHealthEquity Mar2023 FairAccess:CoveragePoliciesin2022 Jan2023 HemophiliaAandB Nov2022 ObesityManagement Sep2022 Menopause:VasomotorSymptoms Dec2022 MultipleSclerosis:CIS,RRMS,andSPMS Jan2023 UnsupportedPriceIncreasesOccurringin2020inCalifornia Oct2022 UnsupportedPriceIncreasesOccurringin2021 Dec2022 SearchAllAssessments&PolicyPapers OurOriginStory. ICERPresidentDr.StevePearsonexplainswhyhefoundedanorganizationtoadvancetheuseofevidencetoimprovehealthcareaffordabilityandaccessforallpatientsandtheirfamilies. FeaturedNews&Insights. Learnaboutourlatestwork. ICERReleasesDraftEvidenceReportonGeneTherapiesforHemophiliaAandB PubliccommentperiodnowopenuntilOctober11,2022;Requeststomakeoralcommentduringpublicmeetingalsobeingaccepted. 09/13/2022 ICERPublishesFinalEvidenceReportandPolicyRecommendationsonTreatmentsforAmyotrophicLateralSclerosis MajorityofindependentappraisalcommitteevotedthatevidenceisadequatetodemonstratethatbothAMX0035andoraledaravone(inpopulationnarrowerthanitslabel)provideanethealthbenefitcomparedtostandardofcare;alsodeterminedthatatcurrentpricingorpriceestimatesboththerapiesrepresenta“low”long-termvalueformoney. 09/13/2022 ICERPublishesEvidenceReportonTreatmentsforObesityManagement Greaterweightlosswasseenwithsemaglutideandwithphentermine/topiramate;lessweightlosswasseenwithliraglutideandwithbupropion/naltrexone. 08/31/2022 GotoNews&Insights TheICERImpact. NewYorkMedicaidpursueddiscounts,manyofwhichwereinlinewithICERreports,whichhavesavedthestateover$500million ReadMore Engagedwithover300patientgroupsandpatientreps Inalandmarkinternationalprogram,HTAagenciesaroundtheworldcannowaccessICER’scustomizableCOVID-19Cost-EffectivenessModel ReadMore LearnMoreAboutICER’sImpact Latest Developments. Werecentlycelebratedour15thanniversary!Learnmore. Dr.MelanieWhittington,ICER’sDirectorofHealthEconomics,receivedtheBernieO’BrienNewInvestigatorAward,whichrecognizesthosewhohaveshownevidenceofexceptionalpromisebasedontheiremergingbodyoftechnicalandscholarlyworkinthefieldof healtheconomics.Learnmore. Listentoourpodcast,“APrescriptionforFairPricing“.SubscribenowonApple,Google,orSpotify. Current PolicyPapers. Easyaccesstoourongoingpolicypapers BarrierstoFairAccess First-everscorecardofseveralkeyappropriateaccesscriteriarevealsvariationacrosslargestpayersbuthighconcordanceforclinicaleligibilitycriteria,steptherapy,andproviderrestrictions;lowerconcordancefoundforformularytieringcriteria. ReadMore UnsupportedPriceIncreases Outof10identifieddrugsthathadsubstantial2020priceincreasesnetofrebatesontopofalreadyhighcurrentspending,sevenwerenotsupportedbynewclinicalevidence;netpriceincreasesonthesesevendrugscostAmericansanadditional$1.67billioninannualdrugspend,ofwhichnearly$1.4billionwasduetoasingledrugalone:Humira. ReadMore EvaluatingandAdvancingHealthTechnologyAssessmentMethodsthatSupportHealthEquity ICERreceivedanewgrantfromTheCommonwealthFundtoevaluateproceduralandmethodologicalchangesthatcouldfurthersupporthealthequitygoalsinhealthtechnologyassessment(HTA).ThefindingsfromthiseffortwillguideICER’supdatetoitsvalueassessmentframeworkandinformtheworkofotherHTAgroupsworldwide. ReadMore Cost-Effectiveness,theevLYG, theQALY,andFairDrugPricing. LearnMore. BacktoTop Weusecookiesonourwebsitetogiveyouthemostrelevantexperiencebyrememberingyourpreferencesandrepeatvisits.Byclicking“AcceptAll”,youconsenttotheuseofALLthecookies.However,youmayvisit"CookieSettings"toprovideacontrolledconsent.CookieSettingsAcceptAllManageconsent Close PrivacyOverview Thiswebsiteusescookiestoimproveyourexperiencewhileyounavigatethroughthewebsite.Outofthese,thecookiesthatarecategorizedasnecessaryarestoredonyourbrowserastheyareessentialfortheworkingofbasicfunctionalitiesofthewebsite.Wealsousethird-partycookiesthathelpusanalyzeandunderstandhowyouusethiswebsite.Thesecookieswillbestoredinyourbrowseronlywithyourconsent.Youalsohavetheoptiontoopt-outofthesecookies.Butoptingoutofsomeofthesecookiesmayaffectyourbrowsingexperience. Necessary Necessary AlwaysEnabled Necessarycookiesareabsolutelyessentialforthewebsitetofunctionproperly.Thesecookiesensurebasicfunctionalitiesandsecurityfeaturesofthewebsite,anonymously. CookieDurationDescriptioncookielawinfo-checkbox-analytics11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookieisusedtostoretheuserconsentforthecookiesinthecategory"Analytics".cookielawinfo-checkbox-functional11monthsThecookieissetbyGDPRcookieconsenttorecordtheuserconsentforthecookiesinthecategory"Functional".cookielawinfo-checkbox-necessary11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookiesisusedtostoretheuserconsentforthecookiesinthecategory"Necessary".cookielawinfo-checkbox-others11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookieisusedtostoretheuserconsentforthecookiesinthecategory"Other.cookielawinfo-checkbox-performance11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookieisusedtostoretheuserconsentforthecookiesinthecategory"Performance".viewed_cookie_policy11monthsThecookieissetbytheGDPRCookieConsentpluginandisusedtostorewhetherornotuserhasconsentedtotheuseofcookies.Itdoesnotstoreanypersonaldata. Functional Functional Functionalcookieshelptoperformcertainfunctionalitieslikesharingthecontentofthewebsiteonsocialmediaplatforms,collectfeedbacks,andotherthird-partyfeatures. Performance Performance Performancecookiesareusedtounderstandandanalyzethekeyperformanceindexesofthewebsitewhichhelpsindeliveringabetteruserexperienceforthevisitors. Analytics Analytics Analyticalcookiesareusedtounderstandhowvisitorsinteractwiththewebsite.Thesecookieshelpprovideinformationonmetricsthenumberofvisitors,bouncerate,trafficsource,etc. Advertisement Advertisement Advertisementcookiesareusedtoprovidevisitorswithrelevantadsandmarketingcampaigns.Thesecookiestrackvisitorsacrosswebsitesandcollectinformationtoprovidecustomizedads. Others Others Otheruncategorizedcookiesarethosethatarebeinganalyzedandhavenotbeenclassifiedintoacategoryasyet. SAVE&ACCEPT
延伸文章資訊
- 1ICER (@icer_review) / Twitter
ICER Analytics™ launched to accelerate the real-world application of ICER reports -- helping paye...
- 2伴隨臨床試驗同步進行藥物經濟研究
而比較兩個方案間的「成本/效果」比值,則可以用遞增成本效果比值(incremental cost-effectiveness ratio, ICER)進行比較,以ICER 較低者為優先。 ICER=.
- 3淺談合理藥價制定分析方法——以阿茲海默症Aduhelm新藥為例
遞增成本效果比值(Incremental cost-effectiveness ratio,ICER) 為其主要指標,公式如下: ICER = (C1-C0) / (E1 - E0).
- 42020-05-29 - 社團法人台灣藥物經濟暨效果研究學會
認識ICER(incremental cost-effectiveness ratio)已經數十寒暑,在學校教這個也十幾 ... 通常在第一象限的狀況,我們會想要計算出成本效果指標ICER (i...
- 5ICER | Working Towards Fair Pricing, Fair Access, & Future ...
ICER provides independent evaluations on the value of medical tests, treatments and delivery syst...